These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 32580786

  • 1. Clinical outcomes after primary prevention defibrillator implantation are better predicted when the left ventricular ejection fraction is assessed by cardiovascular magnetic resonance.
    Champ-Rigot L, Gay P, Seita F, Benouda L, Morello R, Pellissier A, Alexandre J, Saloux E, Milliez P.
    J Cardiovasc Magn Reson; 2020 Jun 25; 22(1):48. PubMed ID: 32580786
    [Abstract] [Full Text] [Related]

  • 2. Prognostic Benefit of Cardiac Magnetic Resonance Over Transthoracic Echocardiography for the Assessment of Ischemic and Nonischemic Dilated Cardiomyopathy Patients Referred for the Evaluation of Primary Prevention Implantable Cardioverter-Defibrillator Therapy.
    Pontone G, Guaricci AI, Andreini D, Solbiati A, Guglielmo M, Mushtaq S, Baggiano A, Beltrama V, Fusini L, Rota C, Segurini C, Conte E, Gripari P, Dello Russo A, Moltrasio M, Tundo F, Lombardi F, Muscogiuri G, Lorenzoni V, Tondo C, Agostoni P, Bartorelli AL, Pepi M.
    Circ Cardiovasc Imaging; 2016 Oct 25; 9(10):. PubMed ID: 27729359
    [Abstract] [Full Text] [Related]

  • 3. Association of cardiovascular magnetic resonance-derived circumferential strain parameters with the risk of ventricular arrhythmia and all-cause mortality in patients with prior myocardial infarction and primary prevention implantable cardioverter defibrillator.
    Paiman EHM, Androulakis AFA, Shahzad R, Tao Q, Zeppenfeld K, Lamb HJ, van der Geest RJ.
    J Cardiovasc Magn Reson; 2019 May 16; 21(1):28. PubMed ID: 31096987
    [Abstract] [Full Text] [Related]

  • 4. Complexity of scar and ventricular arrhythmias in dilated cardiomyopathy of any etiology: Long-term data from the SCARFEAR (Cardiovascular Magnetic Resonance Predictors of Appropriate Implantable Cardioverter-Defibrillator Therapy Delivery) Registry.
    Pedretti S, Vargiu S, Baroni M, Dellegrottaglie S, Lanzarin B, Roghi A, Milazzo A, Quattrocchi G, Lunati M, Pedrotti P.
    Clin Cardiol; 2018 Apr 16; 41(4):494-501. PubMed ID: 29663442
    [Abstract] [Full Text] [Related]

  • 5. Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death.
    Wu KC, Gerstenblith G, Guallar E, Marine JE, Dalal D, Cheng A, Marbán E, Lima JA, Tomaselli GF, Weiss RG.
    Circ Cardiovasc Imaging; 2012 Mar 16; 5(2):178-86. PubMed ID: 22267750
    [Abstract] [Full Text] [Related]

  • 6. Ambulatory blood pressure monitoring, 2D-echo and clinical variables relating to cardiac events in ischaemic cardiomyopathy following cardioverter-defibrillator implantation.
    Antonini L, Pasceri V, Mollica C, Ficili S, Poti G, Aquilani S, Santini M, La Rocca S.
    J Cardiovasc Med (Hagerstown); 2011 May 16; 12(5):334-9. PubMed ID: 21487343
    [Abstract] [Full Text] [Related]

  • 7. Volumetric left ventricular ejection fraction is superior to 2-dimensional echocardiography for risk stratification of patients for primary prevention implantable cardioverter-defibrillator implantation.
    Rayatzadeh H, Patel SJ, Hauser TH, Ngo LL, Shaw JL, Tan A, Buxton AE, Zimetbaum P, Josephson ME, Appelbaum E, Manning WJ, Nezafat R.
    Am J Cardiol; 2013 Apr 15; 111(8):1175-9. PubMed ID: 23375599
    [Abstract] [Full Text] [Related]

  • 8. Left Ventricular Entropy Is a Novel Predictor of Arrhythmic Events in Patients With Dilated Cardiomyopathy Receiving Defibrillators for Primary Prevention.
    Muthalaly RG, Kwong RY, John RM, van der Geest RJ, Tao Q, Schaeffer B, Tanigawa S, Nakamura T, Kaneko K, Tedrow UB, Stevenson WG, Epstein LM, Kapur S, Zei PC, Koplan BA.
    JACC Cardiovasc Imaging; 2019 Jul 15; 12(7 Pt 1):1177-1184. PubMed ID: 30121262
    [Abstract] [Full Text] [Related]

  • 9. Clinical experience regarding safety and diagnostic value of cardiovascular magnetic resonance in patients with a subcutaneous implanted cardioverter/defibrillator (S-ICD) at 1.5 T.
    Holtstiege V, Meier C, Bietenbeck M, Chatzantonis G, Florian A, Köbe J, Reinke F, Eckardt L, Yilmaz A.
    J Cardiovasc Magn Reson; 2020 May 18; 22(1):35. PubMed ID: 32418537
    [Abstract] [Full Text] [Related]

  • 10. The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy.
    Disertori M, Quintarelli S, Mazzola S, Favalli V, Narula N, Arbustini E.
    Europace; 2013 Dec 18; 15(12):1693-701. PubMed ID: 23946316
    [Abstract] [Full Text] [Related]

  • 11. The Occurrence of Implantable Cardioverter Defibrillator Therapies After Generator Replacement in Patients Who No Longer Meet Primary Prevention Indications.
    Kawata H, Hirai T, Doukas D, Hirai R, Steinbrunner J, Wilson J, Noda T, Hsu J, Krummen D, Feld G, Wilber D, Santucci P, Birgersdotter-Green U.
    J Cardiovasc Electrophysiol; 2016 Jun 18; 27(6):724-9. PubMed ID: 26915696
    [Abstract] [Full Text] [Related]

  • 12. Scar heterogeneity on cardiovascular magnetic resonance as a predictor of appropriate implantable cardioverter defibrillator therapy.
    Rayatzadeh H, Tan A, Chan RH, Patel SJ, Hauser TH, Ngo L, Shaw JL, Hong SN, Zimetbaum P, Buxton AE, Josephson ME, Manning WJ, Nezafat R.
    J Cardiovasc Magn Reson; 2013 Apr 10; 15(1):31. PubMed ID: 23574733
    [Abstract] [Full Text] [Related]

  • 13. Left ventricular dimensions predict risk of appropriate shocks but not mortality in cardiac resynchronization therapy-defibrillator recipients with left bundle-branch block and non-ischemic cardiomyopathy.
    Adelstein EC, Schwartzman D, Jain S, Bazaz R, Wang NC, Saba S.
    Europace; 2017 Oct 01; 19(10):1689-1694. PubMed ID: 27856539
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular Magnetic Resonance to Predict Appropriate Implantable Cardioverter Defibrillator Therapy in Ischemic and Nonischemic Cardiomyopathy Patients Using Late Gadolinium Enhancement Border Zone: Comparison of Four Analysis Methods.
    Jablonowski R, Chaudhry U, van der Pals J, Engblom H, Arheden H, Heiberg E, Wu KC, Borgquist R, Carlsson M.
    Circ Cardiovasc Imaging; 2017 Sep 01; 10(9):. PubMed ID: 28838961
    [Abstract] [Full Text] [Related]

  • 15. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis.
    Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, Nothnagel D, Bültel H, Schumm J, Grün S, Ong P, Wagner A, Schneider S, Nassenstein K, Gawaz M, Sechtem U, Bruder O, Mahrholdt H.
    JACC Cardiovasc Imaging; 2013 Apr 01; 6(4):501-11. PubMed ID: 23498675
    [Abstract] [Full Text] [Related]

  • 16. Potential clinical impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for cardioverter defibrillator implantation.
    Joshi SB, Connelly KA, Jimenez-Juan L, Hansen M, Kirpalani A, Dorian P, Mangat I, Al-Hesayen A, Crean AM, Wright GA, Yan AT, Leong-Poi H.
    J Cardiovasc Magn Reson; 2012 Oct 08; 14(1):69. PubMed ID: 23043729
    [Abstract] [Full Text] [Related]

  • 17. Infarct tissue characterization in implantable cardioverter-defibrillator recipients for primary versus secondary prevention following myocardial infarction: a study with contrast-enhancement cardiovascular magnetic resonance imaging.
    Olimulder MA, Kraaier K, Galjee MA, Scholten MF, van Es J, Wagenaar LJ, van der Palen J, von Birgelen C.
    Int J Cardiovasc Imaging; 2013 Jan 08; 29(1):169-76. PubMed ID: 22684301
    [Abstract] [Full Text] [Related]

  • 18. Cardiac Magnetic Resonance for Prophylactic Implantable-Cardioverter Defibrillator Therapy in Ischemic Cardiomyopathy: The DERIVATE-ICM International Registry.
    Pontone G, Guaricci AI, Fusini L, Baggiano A, Guglielmo M, Muscogiuri G, Volpe A, Abete R, Aquaro G, Barison A, Bogaert J, Camastra G, Carigi S, Carrabba N, Casavecchia G, Censi S, Cicala G, De Cecco CN, De Lazzari M, Di Giovine G, Di Roma M, Dobrovie M, Focardi M, Gaibazzi N, Gismondi A, Gravina M, Lanzillo C, Lombardi M, Lorenzoni V, Lozano-Torres J, Martini C, Marzo F, Masi A, Memeo R, Moro C, Nese A, Palumbo A, Pavon AG, Pedrotti P, Marra MP, Pica S, Pradella S, Presicci C, Rabbat MG, Raineri C, Rodriguez-Palomares JF, Sbarbati S, Schoepf UJ, Squeri A, Sverzellati N, Symons R, Tat E, Timpani M, Todiere G, Valentini A, Varga-Szemes A, Masci PG, Schwitter J.
    JACC Cardiovasc Imaging; 2023 Nov 08; 16(11):1387-1400. PubMed ID: 37227329
    [Abstract] [Full Text] [Related]

  • 19. Added Value of 3- Versus 2-Dimensional Echocardiography Left Ventricular Ejection Fraction to Predict Arrhythmic Risk in Patients With Left Ventricular Dysfunction.
    Rodríguez-Zanella H, Muraru D, Secco E, Boccalini F, Azzolina D, Aruta P, Surkova E, Genovese D, Cavalli G, Sammarco G, Ruozi N, Tenaglia RM, Calvillo-Argüelles O, Palermo C, Iliceto S, Badano LP.
    JACC Cardiovasc Imaging; 2019 Oct 08; 12(10):1917-1926. PubMed ID: 30219408
    [Abstract] [Full Text] [Related]

  • 20. The prognostic role of late gadolinium enhancement on cardiac magnetic resonance in patients with nonischemic cardiomyopathy and reduced ejection fraction, implanted with cardioverter defibrillators for primary prevention. A systematic review and meta-analysis.
    Anagnostopoulos I, Kousta M, Kossyvakis C, Lakka E, Paraskevaidis NT, Schizas N, Alexopoulos N, Deftereos S, Giannopoulos G.
    J Interv Card Electrophysiol; 2022 Apr 08; 63(3):523-530. PubMed ID: 34218421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.